-
Roger Li
UrologyChallenging the Standard of Care in NMIBC - 10 day(s) agoDear readers, The standard of care for high-risk non-muscle invasive bladder cancer has long been intravesical BCG. However, due to the ongoing BCG shortage, several…
NMIBC With Roger Li, MD
UrologyDr. Li is a urologic oncologist at Moffitt Cancer Center whose practice focuses on the treatment of bladder, upper tract urothelial, and prostate cancers. His work has been instrumental in the development of clinical trials in the BCG-unresponsive space. He has authored over 100 peer-reviewed manuscripts and serves as reviewer for many international urologic journals.
-
Roger Li
UrologyShared Decision-Making and Quality of Life - 10 day(s) agoDear readers, Shared decision-making is especially important in the setting of managing recurrent disease following failure of BCG. Traditionally, the standard of care for BCG-unresponsive…
-
Roger Li
UrologyRisk Stratification in BCG - 10 day(s) agoDear readers, NMIBC is a clinically and molecularly heterogeneous disease. Risk stratification has traditionally been demarcated based on clinicopathologic characteristics, including tumor grade, stage, multifocality,…
-
Roger Li
UrologyIBCG Consensus Papers Discuss BCG Unresponsive Disease, LG NMIBC - 8 month(s) agoDear Readers, Please find enclosed some exciting new developments in the management of non-muscle invasive bladder cancer (NMIBC). First, I feature studies from two IBCG…
-
Roger Li
UrologyLatest Developments in Non-Muscle Invasive Bladder Cancer - 10 month(s) agoDear readers, Please find enclosed some exciting new developments in the diagnosis and therapeutics for non-muscle invasive bladder cancer, recently reported at AUA 2024 and…
-
Roger Li
UrologyNMIBC: First Results of BOND-003 Study Discussed at SUO 2023 - 1 year(s) agoDear readers, Please find enclosed some exciting new developments in the diagnosis and therapeutics for non-muscle invasive bladder cancer. First, cretostimogene grenadenorepvec, a conditionally replicating…